Product Pipeline

Product & Indication Development Stage
Preclinical Phase 1 Phase 2 Phase 3 Market
Meloxicam
IV Formulation acute post-operative pain Preclinical complete Phase 1 complete Phase 2 complete Phase 3 active Market not started
IM Formulation acute pain Preclinical complete Phase 1 active Phase 2 not started Phase 3 not started Market not started
Dexmedetomidine (“Dex”)
Dex-IN (intranasal) Peri-procedural pain Preclinical complete Phase 1 complete Phase 2 active Phase 3 not started Market not started
Dex-IN (intranasal) Cancer breakthrough pain Preclinical complete Phase 1 complete Phase 2 active Phase 3 not started Market not started
Neuromuscular Blocking Agents (NMBAs)
IV intermediate-acting agent (RP-1000) Preclinical complete Phase 1 active Phase 2 not started Phase 3 not started Market not started
IV ultrashort-acting agent (RP-2000) Preclinical active Phase 1 not started Phase 2 not started Phase 3 not started Market not started
Neuromuscular Blocker Reversal
RP-3000 Preclinical active Phase 1 not started Phase 2 not started Phase 3 not started Market not started

This information reflects public disclosures current as of November 12, 2019

Baudax Bio’s product pipeline will evolve over time as the products move through the drug development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Baudax Bio’s filings with the Securities and Exchange Commission, and actual results may vary materially. Baudax is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.